Roche’s MS drug Ocrevus nears European market

06:57 EST 13 Nov 2017 | pharmaphorum

Roche's new multiple sclerosis drug  Ocrevus (ocrelizumab) gained FDA approval in March, and since then has achieved remarkable revenues of half a billion dollars in the year to date. This looks set to grow in the coming months, as the European C...

Original Article: Roche’s MS drug Ocrevus nears European market


More From BioPortfolio on "Roche’s MS drug Ocrevus nears European market"

Quick Search


Relevant Topics

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...